Managing VMS in Breast Cancer Survivors: Treatment Considerations and Guidelines

In "Managing VMS in Breast Cancer Survivors: Treatment Considerations and Guidelines," our panel explores the multifaceted approach to managing vasomotor symptoms in a breast cancer survivor on adjuvant anastrozole, addressing sleep disturbance, psychosocial impact, oncologic history, and guideline-directed treatment selection. The experts discuss how sleep disruption — now recognized as one of the American Heart Association's Life's Essential Eight — carries significant downstream effects on cardiovascular health, mental health, and daily functioning, making it a critical target in this patient's care. They also address the psychosocial burden of VMS, advocating for open, normalized conversations about menopause, even in unexpected settings like the classroom.

Given the patient's oncologic history, the experts agree on steering away from hormonal therapies as a first-line approach, emphasizing the importance of direct communication with oncologists to assess individual risk. The discussion highlights elinzanetant as a particularly meaningful option for this population, noting that it was specifically studied in breast cancer survivors receiving endocrine therapies such as anastrozole and tamoxifen — a distinction that sets it apart from other non-hormonal treatments. The experts note that the OASIS-4 study evaluated a broad age range of 18 to 70 years and demonstrated benefits for both VMS frequency and sleep, providing the kind of robust safety data that oncologists require before endorsing a treatment.

The conversation closes with a review of NCCN guidelines, which list elinzanetant as a preferred non-hormonal option for VMS in breast cancer patients. The experts emphasize that having a guideline-backed treatment simplifies interdisciplinary collaboration, reduces the need for extensive justification, and ultimately gives both clinicians and patients greater confidence in their treatment decisions.

Our next episode, "Elinzanetant for VMS: Mechanism of Action, Onset, and Treatment Considerations," features two menopause experts discussing the selection of elinzanetant for a breast cancer survivor with severe VMS, exploring its dual NK1 and NK3 receptor antagonism, rapid onset of action, and the critical role of shared decision making in optimizing treatment adherence and long-term survivorship.